A Phase 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
Condition: Erosive Esophagitis Interventions: Drug: BLI5100; Drug: PPI Control Sponsor: Braintree Laboratories Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials